Valeant said on Monday that chief executive Mike Pearson would be stepping down. The Canadian drugmaker also traded blame with its former chief financial officer over providing incorrect information to the company’s auditors that it said led to the filing of erroneous reports with the US securities regulator. The FT's David Crow and Sujeet Indap discuss the company's future.

iTunes Stitcher audioBoom SoundCloud Overcast RSS

Copyright The Financial Times Limited 2017. All rights reserved.

Follow the topics related to this show

Comments have not been enabled for this podcast.